Cargando…
Non-Steroidal Anti-Inflammatory Drugs Do Not Influence the Urinary Testosterone/Epitestosterone Glucuronide Ratio
The UDP Glucuronosyl Transferase (UGT) enzymes are important in the pharmacokinetics, and conjugation, of a variety of drugs including non-steroidal anti-inflammatory drugs (NSAIDs) as well as anabolic androgenic steroids (AAS). Testosterone glucuronidation capacity is strongly associated with a del...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655282/ https://www.ncbi.nlm.nih.gov/pubmed/23720652 http://dx.doi.org/10.3389/fendo.2013.00051 |
_version_ | 1782269861916835840 |
---|---|
author | Lundmark, Jonas Gårevik, Nina Thörngren, John-Olof Garle, Mats Ekström, Lena Rane, Anders Schulze, Jenny J. |
author_facet | Lundmark, Jonas Gårevik, Nina Thörngren, John-Olof Garle, Mats Ekström, Lena Rane, Anders Schulze, Jenny J. |
author_sort | Lundmark, Jonas |
collection | PubMed |
description | The UDP Glucuronosyl Transferase (UGT) enzymes are important in the pharmacokinetics, and conjugation, of a variety of drugs including non-steroidal anti-inflammatory drugs (NSAIDs) as well as anabolic androgenic steroids (AAS). Testosterone glucuronidation capacity is strongly associated with a deletion polymorphism in the UGT2B17 gene. As the use of high doses of NSAIDs has been observed in athletes there is a risk for a drug–drug interaction that may influence the doping tests for AAS. In vitro studies show inhibitory potential on UGT2B7, 2B15, and 2B17 enzymes by NSAIDs. The aim of this study was to investigate if concomitant use of NSAIDs and a single dose of testosterone enanthate would affect the excretion rate of testosterone and epitestosterone glucuronide (TG and EG) as well as the T/E ratio, thereby affecting the outcome of the testosterone doping test. The study was designed as an open, randomized, cross-over study with subjects being their own control. The 23 male healthy volunteers, with either two, one or no allele (ins/ins, ins/del, or del/del) of the UGT2B17 gene, received the maximum recommended dose of NSAID (Ibuprofen or Diclofenac) for 6 days. On day three, 500 mg of testosterone enanthate was administered. Spot urine samples were collected for 17 days. After a wash-out period of 4 months the volunteers received 500 mg testosterone enanthate only, with subsequent spot urine collection for 14 days. The glucuronides of testosterone and epitestosterone were quantified. NSAIDs did not affect the excretion of TG or EG before the administration of testosterone. The concomitant use of NSAIDs and testosterone slightly increased the TG excretion while the EG excretion was less suppressed compared to testosterone use only. The effects of the NSAIDs on the TG and EG excretion did not differ between the UGT2B17 genotype groups. In conclusion, the outcome of testosterone doping tests does not seem to be affected by the use of NSAIDs. |
format | Online Article Text |
id | pubmed-3655282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-36552822013-05-29 Non-Steroidal Anti-Inflammatory Drugs Do Not Influence the Urinary Testosterone/Epitestosterone Glucuronide Ratio Lundmark, Jonas Gårevik, Nina Thörngren, John-Olof Garle, Mats Ekström, Lena Rane, Anders Schulze, Jenny J. Front Endocrinol (Lausanne) Endocrinology The UDP Glucuronosyl Transferase (UGT) enzymes are important in the pharmacokinetics, and conjugation, of a variety of drugs including non-steroidal anti-inflammatory drugs (NSAIDs) as well as anabolic androgenic steroids (AAS). Testosterone glucuronidation capacity is strongly associated with a deletion polymorphism in the UGT2B17 gene. As the use of high doses of NSAIDs has been observed in athletes there is a risk for a drug–drug interaction that may influence the doping tests for AAS. In vitro studies show inhibitory potential on UGT2B7, 2B15, and 2B17 enzymes by NSAIDs. The aim of this study was to investigate if concomitant use of NSAIDs and a single dose of testosterone enanthate would affect the excretion rate of testosterone and epitestosterone glucuronide (TG and EG) as well as the T/E ratio, thereby affecting the outcome of the testosterone doping test. The study was designed as an open, randomized, cross-over study with subjects being their own control. The 23 male healthy volunteers, with either two, one or no allele (ins/ins, ins/del, or del/del) of the UGT2B17 gene, received the maximum recommended dose of NSAID (Ibuprofen or Diclofenac) for 6 days. On day three, 500 mg of testosterone enanthate was administered. Spot urine samples were collected for 17 days. After a wash-out period of 4 months the volunteers received 500 mg testosterone enanthate only, with subsequent spot urine collection for 14 days. The glucuronides of testosterone and epitestosterone were quantified. NSAIDs did not affect the excretion of TG or EG before the administration of testosterone. The concomitant use of NSAIDs and testosterone slightly increased the TG excretion while the EG excretion was less suppressed compared to testosterone use only. The effects of the NSAIDs on the TG and EG excretion did not differ between the UGT2B17 genotype groups. In conclusion, the outcome of testosterone doping tests does not seem to be affected by the use of NSAIDs. Frontiers Media S.A. 2013-05-16 /pmc/articles/PMC3655282/ /pubmed/23720652 http://dx.doi.org/10.3389/fendo.2013.00051 Text en Copyright © 2013 Lundmark, Gårevik, Thörngren, Garle, Ekström, Rane and Schulze. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. |
spellingShingle | Endocrinology Lundmark, Jonas Gårevik, Nina Thörngren, John-Olof Garle, Mats Ekström, Lena Rane, Anders Schulze, Jenny J. Non-Steroidal Anti-Inflammatory Drugs Do Not Influence the Urinary Testosterone/Epitestosterone Glucuronide Ratio |
title | Non-Steroidal Anti-Inflammatory Drugs Do Not Influence the Urinary Testosterone/Epitestosterone Glucuronide Ratio |
title_full | Non-Steroidal Anti-Inflammatory Drugs Do Not Influence the Urinary Testosterone/Epitestosterone Glucuronide Ratio |
title_fullStr | Non-Steroidal Anti-Inflammatory Drugs Do Not Influence the Urinary Testosterone/Epitestosterone Glucuronide Ratio |
title_full_unstemmed | Non-Steroidal Anti-Inflammatory Drugs Do Not Influence the Urinary Testosterone/Epitestosterone Glucuronide Ratio |
title_short | Non-Steroidal Anti-Inflammatory Drugs Do Not Influence the Urinary Testosterone/Epitestosterone Glucuronide Ratio |
title_sort | non-steroidal anti-inflammatory drugs do not influence the urinary testosterone/epitestosterone glucuronide ratio |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655282/ https://www.ncbi.nlm.nih.gov/pubmed/23720652 http://dx.doi.org/10.3389/fendo.2013.00051 |
work_keys_str_mv | AT lundmarkjonas nonsteroidalantiinflammatorydrugsdonotinfluencetheurinarytestosteroneepitestosteroneglucuronideratio AT gareviknina nonsteroidalantiinflammatorydrugsdonotinfluencetheurinarytestosteroneepitestosteroneglucuronideratio AT thorngrenjohnolof nonsteroidalantiinflammatorydrugsdonotinfluencetheurinarytestosteroneepitestosteroneglucuronideratio AT garlemats nonsteroidalantiinflammatorydrugsdonotinfluencetheurinarytestosteroneepitestosteroneglucuronideratio AT ekstromlena nonsteroidalantiinflammatorydrugsdonotinfluencetheurinarytestosteroneepitestosteroneglucuronideratio AT raneanders nonsteroidalantiinflammatorydrugsdonotinfluencetheurinarytestosteroneepitestosteroneglucuronideratio AT schulzejennyj nonsteroidalantiinflammatorydrugsdonotinfluencetheurinarytestosteroneepitestosteroneglucuronideratio |